Evaluating Glycemic Control Efficacy and Safety of the Oral Small Molecule Glucagon-Like Peptide 1 Receptor Agonist Danuglipron in Type 2 Diabetes Patients: A Systemic Review and Meta-Analysis

Overview

Journal Diabetes Metab Syndr Obes

Publisher Dove Medical Press

Specialty Endocrinology

Date 2023 Nov 13

PMID 37954886

Authors

Hareer Fatima

Hussain Sohail Rangwala

Muhammad Saqlain Mustafa

Muhammad Ashir Shafique

Syed Raza Abbas

Azra Rizwan

Tagwa Kalool Fadlalla Ahmed

Ainan Arshad

Affiliations

Soon will be listed here.

Abstract

Introduction: Diabetes Mellitus (DM) is a significant global health concern, with Type 2 DM (T2DM) being highly prevalent. Glucagon-Like Peptide 1 receptor agonists (GLP-1RA), such as Danuglipron, offer potential benefits in T2DM management. This meta-analysis examines the safety and efficacy of Danuglipron, focusing on adverse outcomes and glycemic parameters.

Methods: A systematic search was conducted in PubMed, Scopus, and Cochrane Library for RCTs involving Danuglipron till August 2023, following PRISMA guidelines. The Cochrane risk-of-bias tool was used for quality assessment. Adverse outcomes (diarrhea, nausea, vomiting, headache, decreased appetite, dyspepsia, dizziness) and glycemic parameters like changes in HbA1C, fasting plasma glucose (FPG), and body weight were analyzed.

Results: Four RCTs published from 2021 to 2023 were included. Both doses of Danuglipron were associated with diarrhea (RR=2.66, 90% CI: 1.32 to 5.35, p=0.02), nausea (RR=5.5, 90% CI: 3.4 to 8.88, p<0.00001), and vomiting (RR=5.98, 90% CI: 2.93 to 12.23, p=0.0001). The 120mg dose showed decreased appetite (RR=3.46, 90% CI: 1.57 to 7.62, p=0.01), dyspepsia (RR=4.04, 90% CI: 1.93 to 8.43, p=0.002), and dizziness (RR=5.08, 90% CI: 1.45 to 17.82, p=0.03). Reductions in HbA1C (SMD -1.09, 90% CI -1.39 to -0.8, p < 0.00001), FPG (SMD -1.10, 90% CI -1.46 to -0.75, p < 0.00001), and body weight (SMD -1.08, 90% CI -1.42 to -0.74, p < 0.00001) were observed for both doses.

Conclusion: Danuglipron demonstrates potential for glycemic control and weight reduction in T2DM. Adverse outcomes include diarrhea, nausea, vomiting, and decreased appetite, with dose-related effects. Clinicians must weigh benefits against side effects when considering Danuglipron for T2DM management.

Citing Articles

Insights into the Roles of GLP-1, DPP-4, and SGLT2 at the Crossroads of Cardiovascular, Renal, and Metabolic Pathophysiology.

Gaggini M, Sabatino L, Suman A, Chatzianagnostou K, Vassalle C Cells. 2025; 14(5).

PMID: 40072115 PMC: 11898734. DOI: 10.3390/cells14050387.

Non-clinical and first-in-human characterization of ECC5004/AZD5004, a novel once-daily, oral small-molecule GLP-1 receptor agonist.

Haggag A, Butcher L, Pagnussat S, Davies G, Lundqvist S, Wang W Diabetes Obes Metab. 2024; 27(2):551-562.

PMID: 39495140 PMC: 11701199. DOI: 10.1111/dom.16047.

GLP-1 physiology in obesity and development of incretin-based drugs for chronic weight management.

Holst J Nat Metab. 2024; 6(10):1866-1885.

PMID: 39160334 DOI: 10.1038/s42255-024-01113-9.

Evaluating the effectiveness and safety of various Tirzepatide dosages in the management of Type 2 diabetes mellitus: a network meta-analysis of randomized controlled trials.

Rangwala H, Fatima H, Ali M, Mustafa M, Shafique M, Rangwala B J Diabetes Metab Disord. 2024; 23(1):1199-1222.

PMID: 38932909 PMC: 11196572. DOI: 10.1007/s40200-024-01412-8.

New Molecules in Type 2 Diabetes: Advancements, Challenges and Future Directions.

Chatzianagnostou K, Gaggini M, Suman Florentin A, Simonini L, Vassalle C Int J Mol Sci. 2024; 25(11).

PMID: 38892417 PMC: 11173177. DOI: 10.3390/ijms25116218.

References

Thomas M, Nikooienejad A, Bray R, Cui X, Wilson J, Duffin K . Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes. J Clin Endocrinol Metab. 2020; 106(2):388-396. PMC: 7823251. DOI: 10.1210/clinem/dgaa863. View

Nauck M, Quast D, Wefers J, Meier J . GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Mol Metab. 2020; 46:101102. PMC: 8085572. DOI: 10.1016/j.molmet.2020.101102. View

Page M, McKenzie J, Bossuyt P, Boutron I, Hoffmann T, Mulrow C . The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021; 372:n71. PMC: 8005924. DOI: 10.1136/bmj.n71. View

Hartman M, Sanyal A, Loomba R, Wilson J, Nikooienejad A, Bray R . Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes. Diabetes Care. 2020; 43(6):1352-1355. PMC: 7245348. DOI: 10.2337/dc19-1892. View

Niman S, Hardy J, Goldfaden R, Reid J, Sheikh-Ali M, Sutton D . A Review on the Efficacy and Safety of Oral Semaglutide. Drugs R D. 2021; 21(2):133-148. PMC: 8206300. DOI: 10.1007/s40268-021-00341-8. View

Rahman A, Alqaisi S, Saith S, Alzakhari R, Levy R . The Impact of Glucagon-Like Peptide-1 Receptor Agonist on the Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus: A Meta-Analysis and Systematic Review. Cardiol Res. 2023; 14(4):250-260. PMC: 10409547. DOI: 10.14740/cr1523. View

Chen L, Yun Y, Guo S, Wang X, Xiong M, Zhao T . Discovery of Novel 5,6-Dihydro-1,2,4-triazine Derivatives as Efficacious Glucagon-Like Peptide-1 Receptor Agonists. J Med Chem. 2023; 66(12):7988-8010. DOI: 10.1021/acs.jmedchem.3c00320. View

Cai X, Li J, Wang M, She M, Tang Y, Li J . GLP-1 Treatment Improves Diabetic Retinopathy by Alleviating Autophagy through GLP-1R-ERK1/2-HDAC6 Signaling Pathway. Int J Med Sci. 2017; 14(12):1203-1212. PMC: 5666553. DOI: 10.7150/ijms.20962. View

Ahren B, Atkin S, Charpentier G, Warren M, Wilding J, Birch S . Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials. Diabetes Obes Metab. 2018; 20(9):2210-2219. PMC: 6099440. DOI: 10.1111/dom.13353. View

10.

Sterne J, Savovic J, Page M, Elbers R, Blencowe N, Boutron I . RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019; 366:l4898. DOI: 10.1136/bmj.l4898. View

11.

Griffith D, Edmonds D, Fortin J, Kalgutkar A, Kuzmiski J, Loria P . A Small-Molecule Oral Agonist of the Human Glucagon-like Peptide-1 Receptor. J Med Chem. 2022; 65(12):8208-8226. PMC: 9234956. DOI: 10.1021/acs.jmedchem.1c01856. View

12.

Shankar S, Vella A, Raymond R, Staten M, Calle R, Bergman R . Standardized Mixed-Meal Tolerance and Arginine Stimulation Tests Provide Reproducible and Complementary Measures of β-Cell Function: Results From the Foundation for the National Institutes of Health Biomarkers Consortium Investigative Series. Diabetes Care. 2016; 39(9):1602-13. PMC: 5001146. DOI: 10.2337/dc15-0931. View

13.

Aspnes G, Bagley S, Coffey S, Conn E, Curto J, Edmonds D . 6-Azaspiro[2.5]octanes as small molecule agonists of the human glucagon-like peptide-1 receptor. Bioorg Med Chem Lett. 2023; 94:129454. DOI: 10.1016/j.bmcl.2023.129454. View

14.

Karagiannis T, Avgerinos I, Liakos A, Del Prato S, Matthews D, Tsapas A . Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis. Diabetologia. 2022; 65(8):1251-1261. PMC: 9112245. DOI: 10.1007/s00125-022-05715-4. View

15.

Coskun T, Sloop K, Loghin C, Alsina-Fernandez J, Urva S, Bokvist K . LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Mol Metab. 2018; 18:3-14. PMC: 6308032. DOI: 10.1016/j.molmet.2018.09.009. View

16.

Morita Y, Murayama H, Odawara M, Bauer M . Treatment patterns of drug-naive patients with type 2 diabetes mellitus: a retrospective cohort study using a Japanese hospital database. Diabetol Metab Syndr. 2019; 11:90. PMC: 6824122. DOI: 10.1186/s13098-019-0486-y. View

17.

Saxena A, Frias J, Brown L, Gorman D, Vasas S, Tsamandouras N . Efficacy and Safety of Oral Small Molecule Glucagon-Like Peptide 1 Receptor Agonist Danuglipron for Glycemic Control Among Patients With Type 2 Diabetes: A Randomized Clinical Trial. JAMA Netw Open. 2023; 6(5):e2314493. PMC: 10203889. DOI: 10.1001/jamanetworkopen.2023.14493. View

18.

Araki E, Goto A, Kondo T, Noda M, Noto H, Origasa H . Japanese Clinical Practice Guideline for Diabetes 2019. Diabetol Int. 2020; 11(3):165-223. PMC: 7387396. DOI: 10.1007/s13340-020-00439-5. View

19.

Saxena A, Frias J, Gorman D, Lopez R, Andrawis N, Tsamandouras N . Tolerability, safety and pharmacodynamics of oral, small-molecule glucagon-like peptide-1 receptor agonist danuglipron for type 2 diabetes: A 12-week, randomized, placebo-controlled, Phase 2 study comparing different dose-escalation schemes. Diabetes Obes Metab. 2023; 25(10):2805-2814. DOI: 10.1111/dom.15168. View

20.

Tsapas A, Avgerinos I, Karagiannis T, Malandris K, Manolopoulos A, Andreadis P . Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes: A Systematic Review and Network Meta-analysis. Ann Intern Med. 2020; 173(4):278-286. DOI: 10.7326/M20-0864. View